Comprehensive Analysis of the Expression and Prognosis for MCM4 in Uterine Corpus Endometrial Carcinoma

被引:8
作者
Pei, Li-Peng [1 ]
Zhang, Yun-Zheng [1 ]
Li, Guang-Ying [1 ]
Sun, Jing-Li [1 ]
机构
[1] Gen Hosp Northern Theater Command, Dept Obstet & Gynecol, Shenyang, Peoples R China
关键词
MCM4; uterine corpus endometrial carcinoma; prognosis; multi-omics analysis; RT-qPCR; immunohistochemistry; BREAST-CANCER; PROTEINS; MARKERS;
D O I
10.3389/fgene.2022.890591
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Mini chromosome maintenance protein 4 (MCM4) belongs to the family of mini chromosome maintenance proteins (MCMs) that plays a crucial role in DNA replication and cell cycle regulation. Given that MCM4 has been reported to be aberrantly expressed in a variety of tumor tissues, and is strongly associated with poor patient prognosis, it has rarely been reported in uterine corpus endometrial carcinoma (UCEC).Methods: We explored the role of MCM4 in UCEC through multi-omics analysis, including gene expression levels, survival prognosis, the biological function of interacting proteins, immune infiltration, and diagnostic value. Finally, these results were confirmed by biological experiments.Results: MCM4 was highly expressed in various malignancies including UCEC compared to normal samples and was associated with poor prognosis in patients with UCEC [including OS (HR = 1.74, p = 0.009), PFI (HR = 1.73, p = 0.002), PFI (HR = 2.23, p = 0.003)]. In the Cox regression analysis, MCM4 was an independent prognostic biomarker. Further studies showed those interacting proteins of MCM4 were enriched in DNA repair and cell cycle. Moreover, high expression of MCM4 was accompanied by lower infiltration of immune cells such as Treg cells and B cells. The distribution of MCM4 expression in molecular and immune subtypes was significantly different (p < 0.05), with high expression in the copynumber high (CN_HIGH) molecular subtype and the IFN-gamma dominant (C2) immune subtype. RT-qPCR and immunohistochemistry results also showed that MCM4 expression was significantly upregulated in endometrial cancer tissues and negatively correlated with patient prognosis (p < 0.05). Subsequent biological experiments confirmed that MCM4 promoted cell growth and invasion and inhibited apoptosis in vitro.Conclusion: Therefore, MCM4 could be a new potential biomarker for UCEC.
引用
收藏
页数:14
相关论文
共 44 条
[1]   Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer [J].
Ahluwalia, Pankaj ;
Mondal, Ashis K. ;
Bloomer, Chance ;
Fulzele, Sadanand ;
Jones, Kimya ;
Ananth, Sudha ;
Gahlay, Gagandeep K. ;
Heneidi, Saleh ;
Rojiani, Amyn M. ;
Kota, Vamsi ;
Kolhe, Ravindra .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (15)
[2]   Antitumor Activity of Ohmyungsamycin A through the Regulation of the Skp2-p27 Axis and MCM4 in Human Colorectal Cancer Cells [J].
Byun, Woong Sub ;
Kim, Sunghwa ;
Shin, Yern-Hyerk ;
Kim, Won Kyung ;
Oh, Dong-Chan ;
Lee, Sang Kook .
JOURNAL OF NATURAL PRODUCTS, 2020, 83 (01) :118-126
[3]   A conserved Mcm4 motif is required for Mcm2-7 double-hexamer formation and origin DNA unwinding [J].
Champasan, Kanokwan ;
Blank, Caitlin ;
Friedman, Larry J. ;
Gelles, Jeff ;
Bell, Stephen P. .
ELIFE, 2019, 8
[4]   MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmil, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions [J].
Choy, Bonnie ;
LaLonde, Amy ;
Que, Jianwen ;
Wu, Tongtong ;
Zhou, Zhongren .
HUMAN PATHOLOGY, 2016, 57 :126-135
[5]   Evaluation of the Differences in the Expression of Biogenic Amine-Related mRNAs and Proteins in Endometrioid Endometrial Cancer [J].
Czerwinski, Michal ;
Bednarska-Czerwinska, Anna ;
Zmarzly, Nikola ;
Boron, Dariusz ;
Oplawski, Marcin ;
Grabarek, Beniamin Oskar .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
[6]   Identifier mapping performance for integrating transcriptomics and proteomics experimental results [J].
Day, Roger S. ;
McDade, Kevin K. ;
Chandran, Uma R. ;
Lisovich, Alex ;
Conrads, Thomas P. ;
Hood, Brian L. ;
Kolli, V. S. Kumar ;
Kirchner, David ;
Litzi, Traci ;
Maxwell, G. Larry .
BMC BIOINFORMATICS, 2011, 12
[7]   Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial [J].
de Boer, Stephanie M. ;
Powell, Melanie E. ;
Mileshkin, Linda ;
Katsaros, Dionyssios ;
Bessette, Paul ;
Haie-Meder, Christine ;
Ottevanger, Petronella B. ;
Ledermann, Jonathan A. ;
Khaw, Pearly ;
Colombo, Alessandro ;
Fyles, Anthony ;
Baron, Marie-Helene ;
Jurgenliemk-Schulz, Ina M. ;
Kitchener, Henry C. ;
Nijman, Hans W. ;
Wilson, Godfrey ;
Brooks, Susan ;
Carinelli, Silvestro ;
Provencher, Diane ;
Hanzen, Chantal ;
Lutgens, Ludy C. H. W. ;
Smit, Vincent T. H. B. M. ;
Singh, Naveena ;
Do, Viet ;
D'Amico, Romerai ;
Nout, Remi A. ;
Feeney, Amanda ;
Verhoeven-Adema, Karen W. ;
Putter, Hein ;
Creutzberg, Carien L. .
LANCET ONCOLOGY, 2018, 19 (03) :295-309
[8]   Tumor Microenvironment, Metabolism, and Immunotherapy [J].
DeBerardinis, Ralph J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09) :869-871
[9]   LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy [J].
Friedman, Lisa A. ;
Ring, Kari L. ;
Mills, Anne M. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2020, 39 (03) :203-212
[10]  
Giaginis C, 2010, HISTOL HISTOPATHOL, V25, P351, DOI 10.14670/HH-25.351